AzTrials
AzTrials

Overactive BladderPhase 4NCT00928070

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

A Phase 4 study testing Fesoterodine in people with Overactive Bladder, run by Pfizer at 125 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB). Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Overactive Bladder
What is being tested?
Fesoterodine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
566 participants
Where
125 sitesUnited States
Study dates
Sep 2009to Sep 2011
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • male or female subjects 65 years of age or older
  • OAB symptoms for at least 3 months
  • score 3 or greater on Vulnerable Elderly Survey (VES-13)
  • adequate mobility for independent toileting
  • mean number of at least 2 UUI episodes per 24 hours
  • mean urinary frequency of 8 or more micturitions per 24 hours
  • able to independently complete the bladder diaries

Who cannot join

  • PVR urinary volume greater than 200 ml
  • MMSE score less than 20
  • greater than 15 UUI episodes per 24 hours
  • creatinine clearance less than 30 ml/min
  • an average resting heart rate of greater than or equal to 90 beats per minute

Trial locations and contacts

125 sites in 1 country.

125 sites in 1 country

United States125 sites
  • Pfizer Investigational Site

    Albany, New York, 12208

  • Pfizer Investigational Site

    Altoona, Pennsylvania, 16602

  • Pfizer Investigational Site

    Arkansas City, Kansas, 67005

  • Pfizer Investigational Site

    Atlanta, Georgia, 30067

  • Pfizer Investigational Site

    Aurora, Colorado, 80012

  • Pfizer Investigational Site

    Austin, Texas, 78745

  • Pfizer Investigational Site

    Austin, Texas, 78757

  • Pfizer Investigational Site

    Baltimore, Maryland, 21211

  • Pfizer Investigational Site

    Bethany, Oklahoma, 73008

  • Pfizer Investigational Site

    Birmingham, Alabama, 35233

  • Pfizer Investigational Site

    Birmingham, Alabama, 35294

  • Pfizer Investigational Site

    Bonita Springs, Florida, 34134

  • Pfizer Investigational Site

    Boynton Beach, Florida, 33472

  • Pfizer Investigational Site

    Bristol, Tennessee, 37620

  • Pfizer Investigational Site

    Brooklyn, New York, 11215

  • Pfizer Investigational Site

    Brooksville, Florida, 34601

  • Pfizer Investigational Site

    Burien, Washington, 98166

  • Pfizer Investigational Site

    Cary, North Carolina, 27511

  • Pfizer Investigational Site

    Cary, North Carolina, 27518

  • Pfizer Investigational Site

    Charleston, South Carolina, 29425

  • Pfizer Investigational Site

    Chattanooga, Tennessee, 37404

  • Pfizer Investigational Site

    Clearwater, Florida, 33756

  • Pfizer Investigational Site

    Colorado Springs, Colorado, 80907

  • Pfizer Investigational Site

    Colorado Springs, Colorado, 80909

  • Pfizer Investigational Site

    Columbia, South Carolina, 29201

  • Pfizer Investigational Site

    Corpus Christi, Texas, 78414

  • Pfizer Investigational Site

    Costa Mesa, California, 92626

  • Pfizer Investigational Site

    Daytona Beach, Florida, 32114

  • Pfizer Investigational Site

    DeLand, Florida, 32720

  • Pfizer Investigational Site

    Denver, Colorado, 80211

  • Pfizer Investigational Site

    Denver, Colorado, 80220

  • Pfizer Investigational Site

    East Providence, Rhode Island, 02914

  • Pfizer Investigational Site

    East Providence, Rhode Island, 02915

  • Pfizer Investigational Site

    Edina, Minnesota, 55435

  • Pfizer Investigational Site

    Englewood, Colorado, 80110

  • Pfizer Investigational Site

    Englewood, Colorado, 80113

  • Pfizer Investigational Site

    Erie, Pennsylvania, 16507

  • Pfizer Investigational Site

    Fairfield, California, 94534

  • Pfizer Investigational Site

    Fort Lauderdale, Florida, 33316

  • Pfizer Investigational Site

    Glen Burnie, Maryland, 21061

  • Pfizer Investigational Site

    Glendora, California, 91741

  • Pfizer Investigational Site

    Grand Rapids, Michigan, 49503

  • Pfizer Investigational Site

    Green Valley, Arizona, 85614

  • Pfizer Investigational Site

    Groton, Connecticut, 06340

  • Pfizer Investigational Site

    Houston, Texas, 77062

  • Pfizer Investigational Site

    Houston, Texas, 77074

  • Pfizer Investigational Site

    Jackson, Tennessee, 38305

  • Pfizer Investigational Site

    Kalamazoo, Michigan, 49009

  • Pfizer Investigational Site

    Kansas City, Kansas, 66160-7390

  • Pfizer Investigational Site

    La Mesa, California, 91942

  • Pfizer Investigational Site

    Lake Worth, Florida, 33461

  • Pfizer Investigational Site

    Las Vegas, Nevada, 89119

  • Pfizer Investigational Site

    Leander, Texas, 78641

  • Pfizer Investigational Site

    Lexington, Kentucky, 40503

  • Pfizer Investigational Site

    Lexington, Kentucky, 40504

  • Pfizer Investigational Site

    Lincoln, Nebraska, 68516

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72204

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72223

  • Pfizer Investigational Site

    Long Beach, California, 90806

  • Pfizer Investigational Site

    Longmont, Colorado, 80501

  • Pfizer Investigational Site

    Longview, Texas, 75601

  • Pfizer Investigational Site

    Longview, Texas, 75605

  • Pfizer Investigational Site

    Macon, Georgia, 31217

  • Pfizer Investigational Site

    Melbourne, Florida, 32901

  • Pfizer Investigational Site

    Memphis, Tennessee, 38119

  • Pfizer Investigational Site

    Mesa, Arizona, 85206-1734

  • Pfizer Investigational Site

    Milford, Connecticut, 06460

  • Pfizer Investigational Site

    Mission Viejo, California, 92691

  • Pfizer Investigational Site

    Montgomery, Alabama, 36117

  • Pfizer Investigational Site

    Moorestown, New Jersey, 08057

  • Pfizer Investigational Site

    Murray, Utah, 84107

  • Pfizer Investigational Site

    Murrieta, California, 92562

  • Pfizer Investigational Site

    Myrtle Beach, South Carolina, 29572

  • Pfizer Investigational Site

    Naples, Florida, 34102

  • Pfizer Investigational Site

    New London, Connecticut, 06320

  • Pfizer Investigational Site

    New Port Richey, Florida, 34652

  • Pfizer Investigational Site

    New Port Richey, Florida, 34655

  • Pfizer Investigational Site

    Newburgh, Indiana, 47630

  • Pfizer Investigational Site

    Norman, Oklahoma, 73069

  • Pfizer Investigational Site

    Norwalk, California, 90650

  • Pfizer Investigational Site

    Ocala, Florida, 34471

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73109

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Omaha, Nebraska, 68114

  • Pfizer Investigational Site

    Paramount, California, 90723

  • Pfizer Investigational Site

    Parker, Colorado, 80134

  • Pfizer Investigational Site

    Phoenix, Arizona, 85032

  • Pfizer Investigational Site

    Picayune, Mississippi, 39466

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania, 15243

  • Pfizer Investigational Site

    Plant City, Florida, 33563

  • Pfizer Investigational Site

    Portland, Oregon, 97205

  • Pfizer Investigational Site

    Raleigh, North Carolina, 27612

  • Pfizer Investigational Site

    Rancho Santa Margarita, California, 92688

  • Pfizer Investigational Site

    Richmond, Virginia, 23229

  • Pfizer Investigational Site

    Salt Lake City, Utah, 84103

  • Pfizer Investigational Site

    San Antonio, Texas, 78216

  • Pfizer Investigational Site

    San Antonio, Texas, 78229

  • Pfizer Investigational Site

    San Bernardino, California, 92404

  • Pfizer Investigational Site

    San Diego, California, 92108

  • Pfizer Investigational Site

    Santa Ana, California, 92705

  • Pfizer Investigational Site

    Sarasota, Florida, 34237

  • Pfizer Investigational Site

    Sewell, New Jersey, 08080

  • Pfizer Investigational Site

    Shreveport, Louisiana, 71106

  • Pfizer Investigational Site

    Southaven, Mississippi, 38671

  • Pfizer Investigational Site

    Spokane, Washington, 99216

  • Pfizer Investigational Site

    Springfield, Illinois, 62702

  • Pfizer Investigational Site

    Springfield, Illinois, 62703

  • Pfizer Investigational Site

    Springfield, Massachusetts, 01103

  • Pfizer Investigational Site

    St Louis, Missouri, 63117

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33710

  • Pfizer Investigational Site

    Staten Island, New York, 10304

  • Pfizer Investigational Site

    Temecula, California, 92591

  • Pfizer Investigational Site

    Temple, Texas, 76508

  • Pfizer Investigational Site

    Towson, Maryland, 21204

  • Pfizer Investigational Site

    Trinity, Florida, 34655

  • Pfizer Investigational Site

    Tucson, Arizona, 85712

  • Pfizer Investigational Site

    Tuscon, Arizona, 85710

  • Pfizer Investigational Site

    Vacaville, California, 95688

  • Pfizer Investigational Site

    Wellington, Florida, 33449

  • Pfizer Investigational Site

    West Jordan, Utah, 84088

  • Pfizer Investigational Site

    Wichita, Kansas, 67205

  • Pfizer Investigational Site

    Wichita, Kansas, 67207

  • Pfizer Investigational Site

    Williamsville, New York, 14221

  • Pfizer Investigational Site

    Willoughby Hills, Ohio, 44094

  • Pfizer Investigational Site

    Winter Haven, Florida, 33880

Other trials in United States

About this study

Official title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).

Being tested
Fesoterodine, Placebo
Keywords
Urgency Urinary Incontinence OAB
Medical subject headings
Urinary Bladder, Overactive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FesoterodineDrug

    Fesoterodine 4 mg and 8 mg

  • PlaceboDrug

    Placebo sham 4 mg and 8 mg

Study groups in NCT00928070
Study groupRoleWhat they receive
FesoterodineExperimentalNot described
Receives: Drug: Fesoterodine
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours

    UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline

  2. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12

    UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 12

Secondary outcomes (24)
  1. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4

    UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 4

  2. Percent Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12

    Percent change of UUI episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

    Measured: Baseline, Week 4, 12

  3. Mean Number of Micturitions Per 24 Hours

    Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.

    Measured: Baseline

  4. Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12

    Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.

    Measured: Baseline, Week 4, 12

  5. Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12

    Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

    Measured: Baseline, Week 4, 12

  6. Mean Number of Micturition-related Urgency Episodes Per 24 Hours

    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline

  7. Change From Baseline in Mean Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12

    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 4, 12

  8. Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12

    Percent change of micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

    Measured: Baseline, Week 4, 12

  9. Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours

    Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.

    Measured: Baseline

  10. Change From Baseline in Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12

    Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.

    Measured: Baseline, Week 4, 12

  11. Percent Change From Baseline in Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12

    Percent change of nocturnal micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

    Measured: Baseline, Week 4, 12

  12. Frequency-Urgency Sum Rating Per 24 Hours

    Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine.

    Measured: Baseline

  13. Change From Baseline in Frequency-Urgency Sum Rating Per 24 Hours at Week 4 and 12

    Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine. Numerical decrease indicates improvement.

    Measured: Baseline, Week 4, 12

  14. Change From Baseline in Mean Number of Protective Undergarments Changed Due to Urinary Leakage Per 24 Hours at Week 4 and 12

    Protective Undergarments included pads, protective padding, protective underwear (pull up), and briefs (diaper). The mean number of undergarments changed per 24 hours was calculated as the total number of undergarments changed divided by the total number of diary days collected at that visit. Change from baseline values were reported at week 4 for subsets of population with baseline values less than or equal to (=<) 3.5 and more than (>) 3.5 undergarments/day and at Week 12 for subsets of population with baseline values =< 2.5 and > 2.5 undergarments/day.

    Measured: Baseline, Week 4, 12

  15. Percentage of Participants With Change From Screening in Patient Perception of Bladder Condition (PPBC) at Week 4 and 12

    PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Deterioration=score difference is greater than 0; no change=score difference is 0; minor improvement=score difference is -1; major difference=score difference is less than or equal to -2.

    Measured: Screening, Week 4, 12

  16. Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score

    OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.

    Measured: Baseline

  17. Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12

    OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.

    Measured: Baseline, Week 4, 12

  18. Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)

    OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.

    Measured: Baseline

  19. Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12

    OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.

    Measured: Baseline, Week 4, 12

  20. Overactive Bladder Satisfaction Questionnaire (OAB-S) Total Score on Satisfaction With OAB Control

    OAB-S: a validated self-administered instrument that evaluates OAB medication expectations, daily life with AB, and satisfaction with OAB medication and includes 3 stand-alone items that assess overall expectation, satisfaction, and willingness to continue treatment. Satisfaction coded on scale of 1 to 5: (1=very satisfied to 5=very dissatisfied). Coding reversed algorithmically and results transformed: total score range 0 to100. Higher final response value associated with better satisfaction.

    Measured: Week 12

  21. Percentage of Participants With Overactive Bladder Satisfaction Questionnaire (OAB-S) Global Medication Satisfaction Question Response

    Participant's response to question, "overall, how satisfied are you with your OAB medication?" was obtained on a 5 point scale, 1- very satisfied, 2- somewhat satisfied, 3- neither dissatisfied nor satisfied, 4- somewhat dissatisfied and 5- very dissatisfied. Response values 1 and 2 were combined into "satisfied", and 4 and 5 were combined into "dissatisfied".

    Measured: Week 12

  22. Mini Mental State Examination (MMSE)

    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state.

    Measured: Screening

  23. Change From Screening in Mini Mental State Examination (MMSE) Score at Week 12

    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state. Change: mean score at Week X minus mean score at baseline

    Measured: Screening, Week 12

  24. Change From Baseline in Post Void Residual (PVR) Volume at Week 4 and 12

    PVR volume is defined as volume of urine remaining in the bladder immediately after urination.

    Measured: Baseline, Week 4, 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2009 (estimated)
  2. Study startSep 2009
  3. Primary completionSep 2011
  4. Study completionSep 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
566 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00928070
Sponsor's protocol ID
A0221049
Status last verified
Dec 2012
First submitted
24 Jun 2009
Last updated
17 Jan 2013
Data monitoring committee
Yes

Publications

  • Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.

    PubMed 37160401
  • Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, Ouslander JG, Sun F, Gong J, Bavendam T. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014 Feb;191(2):395-404. doi: 10.1016/j.juro.2013.08.027. Epub 2013 Aug 21.

    PubMed 23973522

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fesoterodine in people with Overactive Bladder, run by Pfizer at 125 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 125 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00928070, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in